**Direct Comparison of Risankizumab and Fumaric Acid Esters in Systemic–Therapy-Naïve Patients**

With Moderate to Severe Plaque Psoriasis: A Randomized Controlled Trial

D. Thaçi, K. Eyerich, A. Pinter, M. Sebastian, K. Unnebrink, S. Rubant, D. A. Williams,

P. Weisenseel

Supplementary Materials

Figure S1. PASI efficacy outcomes (OC analysis). ITT population. Mean change from baseline in overall PASI. *P<.001 vs FAEs. *P* values calculated from ANCOVA with baseline value and treatment in the model. ANCOVA, analysis of covariance. FAEs, fumaric acid esters (oral formulation); ITT, intent to treat; OC, observed case; RZB, risankizumab.

Figure S2. Improvement from baseline in palmoplantar psoriasis, scalp, and nail outcomes (OC analysis). Mean percent improvement from baseline in (a) PPASI, (b) PSSI, and (c) NAPSI. ITT population. *P<.001 vs FAEs. P values calculated from ANCOVA with baseline value and treatment in the model. ANCOVA, analysis of covariance; FAEs, fumaric acid esters (oral formulation); ITT, intent to treat; NAPSI, Nail Assessment in Psoriasis and Psoriatic Arthritis; OC, observed case; PPASI, Palmoplantar Psoriasis Area Severity Index; PSSI, Psoriatic Scalp Severity Index; RZB, risankizumab.